Cargando…

The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study

BACKGROUND: The objective of this study was to investigate whether androgen deprivation therapy (ADT) with gonadotropin-releasing hormone agonist (GnRHa) in prostate cancer (Pca) patients is associated with cardiovascular disease in the cohort based from the entire Korean population. METHODS: Using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shim, Myungsun, Bang, Woo Jin, Oh, Cheol Young, Lee, Yong Seong, Jeon, Seong Soo, Ahn, Hanjong, Ju, Young-Su, Cho, Jin Seon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995814/ https://www.ncbi.nlm.nih.gov/pubmed/31997617 http://dx.doi.org/10.3346/jkms.2020.35.e47

Ejemplares similares

Risk of dementia and Parkinson’s disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study
por: Shim, Myungsun, et al.
Publicado: (2020)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

Androgen deprivation therapy and risk of cognitive dysfunction in men with prostate cancer: is there a possible link?
por: Shim, Myungsun, et al.
Publicado: (2022)

A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer
por: Asakawa, Jumpei, et al.
Publicado: (2018)

Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty
por: Shim, Young Suk, et al.
Publicado: (2020)

The role of gonadotropin-releasing hormone agonists in female fertility preservation
por: Lee, Jae Hoon, et al.
Publicado: (2021)

Effect of gonadotropin-releasing hormone agonist monotherapy and combination therapy with growth hormone on final adult height in girls with central precocious puberty
por: Cho, Ah Young, et al.
Publicado: (2023)

Gonadotropin releasing hormone agonists: Expanding vistas
por: Magon, Navneet
Publicado: (2011)

Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist
por: Lee, Min Jin, et al.
Publicado: (2017)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
por: Han, Eun Jin, et al.
Publicado: (2013)

Final height after gonadotropin-releasing hormone agonists with or without growth hormone in Korean girls with central precocious puberty and early puberty
por: Kwon, Eun Byul, et al.
Publicado: (2015)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
por: Keane, Fergus, et al.
Publicado: (2016)

Gonadotropin-Releasing Hormone Agonist Therapy and Obesity in Girls
por: Shiasi Arani, Kobra, et al.
Publicado: (2015)

Gonadotropin-Releasing Hormone Agonist Induced Pituitary Apoplexy
por: Yu, Xiaoling, et al.
Publicado: (2021)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
por: Zhou, Feng, et al.
Publicado: (2016)

Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
por: Choi, Seungtaek, et al.
Publicado: (2011)

Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone
por: Jung, Mo Kyung, et al.
Publicado: (2014)

Agonist-induced internalization and downregulation of gonadotropin-releasing hormone receptors
por: Finch, Ann R., et al.
Publicado: (2009)

Apoptotic Death of Prostate Cancer Cells by a Gonadotropin-Releasing Hormone-II Antagonist
por: Park, Sumi, et al.
Publicado: (2014)

Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy
por: Bang, Woo Jin, et al.
Publicado: (2022)

Effect of Diabetes Mellitus on Symptomatic Improvement After Surgery for Benign Prostatic Hyperplasia in Patients With Lower Urinary Tract Symptom and its Relations With Prostatic Urethral Angulation
por: Jo, Jung Ki, et al.
Publicado: (2023)

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Hydrogen peroxide suppresses excitability of gonadotropin-releasing hormone neurons in adult mouse
por: Rijal, Santosh, et al.
Publicado: (2022)

Increased Risk of Pneumonia in Patients Receiving Gonadotropin-Releasing Hormone Agonists for Prostate Cancer
por: Chung, Shiu-Dong, et al.
Publicado: (2014)

The association between family history of prostate cancer and development of prostate cancer among Korean population: A prospective cohort study using KoGES data
por: Choi, Hyo Geun, et al.
Publicado: (2021)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
por: Castillo, Juan Carlos, et al.
Publicado: (2020)

Is gonadotropin-releasing hormone agonist usage really leading to thyroid dysfunction?
por: Yilmaz, Nafiye, et al.
Publicado: (2019)

Pituitary Apoplexy Secondary to Gonadotropin-Releasing Hormone Agonist for Breast Cancer
por: Mastandrea, Katherine, et al.
Publicado: (2023)

Half-dose, long-acting gonadotropin-releasing hormone agonist (Diphereline) is comparable with daily injections of short-acting gonadotropin-releasing hormone agonist (Suprefact) in IVF/ICSI cycles
por: Tehraninejad, Ensieh Sh., et al.
Publicado: (2010)

Effects of human growth hormone on gonadotropin-releasing hormone neurons in mice
por: Bhattarai, Janardhan P., et al.
Publicado: (2010)

Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
por: Baek, Joon-Woo, et al.
Publicado: (2014)

Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial
por: Shim, Myungsun, et al.
Publicado: (2021)

Editorial Comment to Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer
por: Kawahara, Takashi
Publicado: (2020)

A randomized controlled trial of gonadotropin-releasing hormone agonist versus gonadotropin-releasing hormone antagonist in Iranian infertile couples: oocyte gene expression
por: Hoseini, Fatemeh Sadat, et al.
Publicado: (2014)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer
por: Shin, Jae Jun, et al.
Publicado: (2020)

Final Oocyte Maturation in Assisted Reproduction with Human Chorionic Gonadotropin and Gonadotropin-releasing Hormone agonist (Dual Trigger)
por: de Oliveira, Sofia Andrade, et al.
Publicado: (2016)

Effects of gonadotropin-releasing hormone agonist on human chorionic gonadotropin activity in granulosa cells of immature female rats
por: TUNGMAHASUK, Doungrut, et al.
Publicado: (2017)

Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves the outcome of intrauterine insemination
por: Halim, Binarwan, et al.
Publicado: (2022)

Comparison of the clinical outcome of frozen-thawed embryo transfer with and without pretreatment with a gonadotropin-releasing hormone agonist
por: Kang, Jieun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h81gmbaiaunvrvigmu65ap6j12